Treating Disorders Associated with IL-20 Receptor-Mediated Signaling Pathway by Blocking IL-20 Receptor Activity
AssigneeNational Cheng Kung University
InventorMing-Shi Chang
Life of this patent
Estimating the term…
Abstract
Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.
Claims22
A method for treating a disorder associated with a signaling pathway mediated by an IL-20 receptor, comprising administering to a subject in need thereof an effective amount of an agent that suppresses the activity of the IL-20 receptor.
An isolated antibody that binds to IL-20R1, wherein the antibody comprises (i) a heavy chain variable region containing the same complementarity determining regions (CDRs) as those in the heavy chain variable region of monoclonal antibody mAb7GW and a light chain variable region containing the same CDRs as those in the light chain variable region of mAb7GW;
- or (ii) a heavy chain variable region containing the same CDRs as those in the heavy chain variable region of monoclonal antibody mAb51D and a light chain variable region containing the same CDRs as those in the light chain variable region of mAb51D.
(canceled)
22-23. (canceled)
Dependencies are inferred from the claim text.